Collectively, these epidemiological findings suggested that circulating adiponectin may be a useful biomarker of catabolic processes, such as sarcopenia and cachexia, in the chronic conditions, which are frequently associated with weight and muscle loss as well as high mortality risk among the elderly. Here, ADIPOQ is linked to sarcopenia.